Trulieve Cannabis Corp. (TRLV) Financial Statements
Trulieve Cannabis Corp. (TRLV) reported trailing twelve-month revenue of $1.1B (down 3.9% year on year) and net income of -$470.3M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $186.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRLVTrulieve Cannabis Corp.Follow TRLV — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.93 | 1.22 | 1.13 | 1.19 | 1.18 | 1.14 | |
| Gross profit | 0.57 | 0.69 | 0.59 | 0.72 | 0.71 | 0.68 | |
| Operating income | 0.20 | 0.05 | -0.22 | 0.10 | 0.14 | -0.28 | |
| Pre-tax income | 0.18 | -0.02 | -0.28 | 0.04 | 0.09 | -0.33 | |
| Income tax | 0.15 | 0.16 | 0.15 | 0.20 | 0.21 | 0.14 | |
| Net income | 0.02 | -0.25 | -0.53 | -0.16 | -0.12 | -0.47 | |
| Diluted EPS ($) | 0.21 | -0.95 | -2.28 | -0.79 | -0.58 | -2.44 | |
| Diluted shares (bn) | 0.147 | 0.188 | 0.189 | 0.190 | 0.191 | — |
USD billions · SEC XBRL
Trulieve Cannabis Corp. — questions
- What is Trulieve Cannabis Corp.'s revenue?
- $1.1B over the twelve months to 2026-06-30, down 3.9% year on year, from its 10-Q and 10-K filings.
- What is Trulieve Cannabis Corp.'s net income?
- -$470.3M over the twelve months to 2026-06-30.
- What is Trulieve Cannabis Corp.'s free cash flow?
- $186.2M over the twelve months to 2026-06-30.
- What are Trulieve Cannabis Corp.'s diluted earnings per share?
- $-2.44 over the twelve months to 2026-06-30.
Every figure on this page comes from Trulieve Cannabis Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.